Francesco Mancini1, Sara Nannarone2, Sandra Buratta3, Giuseppina Ferrara3, Anna Maria Stabile4, Matteo Vuerich5, Isabella Santinelli5, Alessandra Pistilli4, Elisabetta Chiaradia6. 1. Laboratory of Proteomics and Cellular Biochemistry, Department of Veterinary Medicine, University of Perugia, Perugia, Italy. 2. Sport Horse Research Centre, Department of Veterinary Medicine, University of Perugia, Perugia, Italy; Veterinary Teaching Hospital, Department of Veterinary Medicine, University of Perugia, Perugia, Italy. 3. Laboratory of Biochemistry and Molecular Biology, Department of Chemistry, Biology and Biotechnology, University of Perugia, Perugia, Italy. 4. Laboratory of Anatomy, Department of Surgery and Biomedical Sciences, University of Perugia, Perugia, Italy. 5. Veterinary Teaching Hospital, Department of Veterinary Medicine, University of Perugia, Perugia, Italy. 6. Laboratory of Proteomics and Cellular Biochemistry, Department of Veterinary Medicine, University of Perugia, Perugia, Italy; Sport Horse Research Centre, Department of Veterinary Medicine, University of Perugia, Perugia, Italy. Electronic address: elisabetta.chiaradia@unipg.it.
Abstract
OBJECTIVE: To assess the effects of xylazine and dexmedetomidine on equine chondrocytes, in vitro. STUDY DESIGN: Prospective, experimental study. STUDY MATERIAL: Equine articular chondrocytes from five male horses. METHODS: Chondrocytes were isolated from healthy equine articular cartilage of the metacarpo/metatarsophalangeal joints. Cell viability was assessed using the WST-8 assay by exposing chondrocytes to xylazine (0.5, 1, 2, 4, 8, 16.6, 25, 50 mg mL-1) or dexmedetomidine (0.001, 0.005, 0.01, 0.05, 0.175, 0.25 mg mL-1) for 15, 30 and 60 minutes. Based on the results of these tests, cells were treated with xylazine (1, 4, 25 mg mL-1) or dexmedetomidine (0.05, 0.175, 0.25 mg mL-1) for 15 minutes to further evaluate: cell viability by neutral red uptake; cell membrane integrity by lactate dehydrogenase release and by fluorescence microscopy with Hoechst 33342 and propidium iodide (PI), and apoptosis by flow cytometry using double staining with annexin V-fluorescein isothiocyanate/PI and by cell morphology. RESULTS: Both drugs reduced cell viability in a dose-dependent manner. Specifically, all xylazine concentrations, except 0.5 mg mL-1 and 1 mg mL-1, significantly reduced cell viability, whereas the effects of dexmedetomidine were evident only at 0.175 mg mL-1 and 0.25 mg mL-1. The highest concentrations of xylazine (25 mg mL-1) and dexmedetomidine (0.25 mg mL-1) caused loss of membrane integrity. Cell morphology and flow cytometry analyses demonstrated signs of late apoptosis in xylazine-treated cells, and signs of late apoptosis and necrosis in dexmedetomidine-treated cells. CONCLUSIONS AND CLINICAL RELEVANCE: This study offers new insights into the potential chondrotoxicity induced by dexmedetomidine and xylazine. Therefore, the intra-articular administration of α2-agonists should be conducted with care, especially for doses of ≥ 4 mg mL-1 of xylazine and 0.175 mg mL-1 and 0.25 mg mL-1 of dexmedetomidine.
OBJECTIVE: To assess the effects of xylazine and dexmedetomidine on equine chondrocytes, in vitro. STUDY DESIGN: Prospective, experimental study. STUDY MATERIAL: Equine articular chondrocytes from five male horses. METHODS: Chondrocytes were isolated from healthy equine articular cartilage of the metacarpo/metatarsophalangeal joints. Cell viability was assessed using the WST-8 assay by exposing chondrocytes to xylazine (0.5, 1, 2, 4, 8, 16.6, 25, 50 mg mL-1) or dexmedetomidine (0.001, 0.005, 0.01, 0.05, 0.175, 0.25 mg mL-1) for 15, 30 and 60 minutes. Based on the results of these tests, cells were treated with xylazine (1, 4, 25 mg mL-1) or dexmedetomidine (0.05, 0.175, 0.25 mg mL-1) for 15 minutes to further evaluate: cell viability by neutral red uptake; cell membrane integrity by lactate dehydrogenase release and by fluorescence microscopy with Hoechst 33342 and propidium iodide (PI), and apoptosis by flow cytometry using double staining with annexin V-fluorescein isothiocyanate/PI and by cell morphology. RESULTS: Both drugs reduced cell viability in a dose-dependent manner. Specifically, all xylazine concentrations, except 0.5 mg mL-1 and 1 mg mL-1, significantly reduced cell viability, whereas the effects of dexmedetomidine were evident only at 0.175 mg mL-1 and 0.25 mg mL-1. The highest concentrations of xylazine (25 mg mL-1) and dexmedetomidine (0.25 mg mL-1) caused loss of membrane integrity. Cell morphology and flow cytometry analyses demonstrated signs of late apoptosis in xylazine-treated cells, and signs of late apoptosis and necrosis in dexmedetomidine-treated cells. CONCLUSIONS AND CLINICAL RELEVANCE: This study offers new insights into the potential chondrotoxicity induced by dexmedetomidine and xylazine. Therefore, the intra-articular administration of α2-agonists should be conducted with care, especially for doses of ≥ 4 mg mL-1 of xylazine and 0.175 mg mL-1 and 0.25 mg mL-1 of dexmedetomidine.
Authors: Alessandra Di Salvo; Elisabetta Chiaradia; Giorgia Della Rocca; Mario Giorgi; Francesco Mancini; Maria Luisa Marenzoni; Maria Beatrice Conti; Sara Nannarone Journal: Vet Q Date: 2018-12 Impact factor: 3.320
Authors: Elisabetta Chiaradia; Marco Pepe; Pier Luigi Orvietani; Giovanni Renzone; Alessandro Magini; Monica Sforna; Carla Emiliani; Antonio Di Meo; Andrea Scaloni Journal: Int J Mol Sci Date: 2019-12-07 Impact factor: 5.923